title: Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax).
abstract: Fialuridine (FIAU, 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil) is toxic to liver, heart, muscle, and nerve in clinical trials for chronic viral hepatitis (CH). Mitochondrial toxicity was hypothesized. To address pathophysiologic mechanisms, we examined mitochondrial changes in FIAU-treated woodchucks (WC) with CH from woodchuck hepatitis virus infection. WC (with and without CH from woodchuck hepatitis virus infection) were treated with FIAU (1.5 mg/kg/day) for 12 weeks. WC were killed. Liver, heart, skeletal muscle, and kidney samples underwent DNA extraction and were analyzed ultrastructurally (transmission electron microscopy). Myocardium, skeletal muscles, and liver samples were analyzed histologically. Abundance of hepatic, myocardial, muscle, and kidney mtDNA decreased in FIAU-treated WC, but the magnitude varied. mtDNA decreased 55% in heart, 65% in kidney, 74% in liver, and 87% in muscle (p < 0.02 for each tissue: FIAU-treated versus FIAU-untreated). Cellular damage was characterized ultrastructurally by mitochondrial enlargement, cristae dissolution, and lipid droplets. Lipid droplets found in the heart, diaphragm, biceps, and liver were sufficient to identify FIAU-treated WC (p < 0.05 each). Widespread mitochondrial damage to many tissues resulted from chronic FIAU treatment and occurred irrespective of CH. It manifested with mtDNA depletion, intracytoplasmic lipid droplets, and destroyed mitochondrial cristae. Defective mtDNA replication with mtDNA depletion seems central to the subcellular pathophysiology of altered energy metabolism and multiorgan failure in FIAU toxicity.
authors.affiliation: Department of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Ohio 45267-0529, USA.
authors.forename: W
authors.initials: W
authors.lastname: Lewis
authors.forename: B
authors.initials: B
authors.lastname: Griniuviene
authors.forename: K O
authors.initials: KO
authors.lastname: Tankersley
authors.forename: E S
authors.initials: ES
authors.lastname: Levine
authors.forename: R
authors.initials: R
authors.lastname: Montione
authors.forename: L
authors.initials: L
authors.lastname: Engelman
authors.forename: G
authors.initials: G
authors.lastname: de Courten-Myers
authors.forename: M A
authors.initials: MA
authors.lastname: Ascenzi
authors.forename: W E
authors.initials: WE
authors.lastname: Hornbuckle
authors.forename: J L
authors.initials: JL
authors.lastname: Gerin
authors.forename: B C
authors.initials: BC
authors.lastname: Tennant
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000633:toxicity*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000633:toxicity; D004249:DNA Damage; D004272:DNA, Mitochondrial / Q000187:drug effects* / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D006509:Hepatitis B / Q000473:pathology* / Q000662:veterinary; D017919:Hepatitis B Virus, Woodchuck; D007668:Kidney / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D008055:Lipids / Q000032:analysis*; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D008392:Marmota; D008928:Mitochondria / Q000187:drug effects / Q000473:pathology*; D008931:Mitochondria, Muscle / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D018482:Muscle, Skeletal / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D009206:Myocardium / Q000473:pathology / Q000648:ultrastructure
chemical_list: D000998:Antiviral Agents; D004272:DNA, Mitochondrial; D008055:Lipids; D001086:Arabinofuranosyluracil; C043457:fialuridine